Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
{{output}}
ESR1 (estrogen receptor 1) hotspot mutations are major contributors to therapeutic resistance in estrogen receptor-positive (ER+) breast cancer. Such mutations confer estrogen independence to ERα, providing a selective advantage in the presence of estrogen-de... ...
